ImmunoPrecise Antibodies (IPA) Competitors

CASI Pharmaceuticals (NASDAQ:CASI) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings.

Does the media prefer CASI or IPA?

In the previous week, ImmunoPrecise Antibodies had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for ImmunoPrecise Antibodies and 0 mentions for CASI Pharmaceuticals. ImmunoPrecise Antibodies' average media sentiment score of 0.54 beat CASI Pharmaceuticals' score of 0.00 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
ImmunoPrecise Antibodies	Positive

Do insiders and institutionals hold more shares of CASI or IPA?

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, CASI or IPA?

CASI Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.

Is CASI or IPA more profitable?

ImmunoPrecise Antibodies has a net margin of -114.50% compared to CASI Pharmaceuticals' net margin of -143.18%. ImmunoPrecise Antibodies' return on equity of -70.69% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%
ImmunoPrecise Antibodies	-114.50%	-70.69%	-41.64%

Which has stronger earnings and valuation, CASI or IPA?

ImmunoPrecise Antibodies has higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$22.06M	1.86	-$26.94M	-$2.23	-1.19
ImmunoPrecise Antibodies	$24.07M	0.48	-$20.13M	-$0.78	-0.51

Do analysts prefer CASI or IPA?

CASI Pharmaceuticals currently has a consensus price target of $6.00, suggesting a potential upside of 126.42%. ImmunoPrecise Antibodies has a consensus price target of $5.00, suggesting a potential upside of 1,150.00%. Given ImmunoPrecise Antibodies' higher possible upside, analysts plainly believe ImmunoPrecise Antibodies is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ImmunoPrecise Antibodies	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in CASI or IPA?

CASI Pharmaceuticals received 189 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 91.67% of users gave ImmunoPrecise Antibodies an outperform vote while only 50.25% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
CASI Pharmaceuticals	Outperform Votes 200 50.25%	Underperform Votes 198 49.75%
ImmunoPrecise Antibodies	Outperform Votes 11 91.67%	Underperform Votes 1 8.33%

Summary

ImmunoPrecise Antibodies beats CASI Pharmaceuticals on 12 of the 17 factors compared between the two stocks.